

## Ethiopia

### Support for Vaccine: Pneumococcal This Decision Letter sets out the Programme Terms of a Programme.

1. Country:	Ethiopia										
2. Vaccine grant number:	10-ETH-08b-Y, 1114-ETH-12b-X, 1517-ETH-12b-X, 1820-ETH-12a-X										
3. Date of Decision Letter:	24 July 2019										
4. Date of the Partnership Framework Agreement:	23 July 2013										
5. Programme title:	New Vaccine Support (NVS), Pneumococcal , Routine										
6. Vaccine type:	Pneumococcal										
7. Requested product presentation and formulation of vaccine:	PCV10, 2 dose(s) per vial, LIQUID										
8. Programme Duration: <sup>1</sup>	2011-2020										
9. Programme Budget (indicative): <sup>2</sup>	(subject to the terms of the Partnership Framework Agreement, if applicable)										
	<table border="1"> <thead> <tr> <th></th> <th>2011-2018</th> <th>2019</th> <th>2020</th> <th>Total<sup>2</sup></th> </tr> </thead> <tbody> <tr> <td>Programme Budget (US\$)</td> <td>309,551,926</td> <td>30,124,000</td> <td>28,537,500</td> <td>368,213,426</td> </tr> </tbody> </table>		2011-2018	2019	2020	Total <sup>2</sup>	Programme Budget (US\$)	309,551,926	30,124,000	28,537,500	368,213,426
	2011-2018	2019	2020	Total <sup>2</sup>							
Programme Budget (US\$)	309,551,926	30,124,000	28,537,500	368,213,426							
10. Vaccine introduction grant	A VIG of US\$ 881,500 was disbursed on 11 October 2011. Unspent balance of US\$ 289,211 was reprogrammed to the Health Systems Strengthening grant in August 2018.										
11. Indicative Annual Amounts: <sup>3</sup>	(subject to the terms of the Partnership Framework Agreement, if applicable)										
	<table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Gavi funds</th> <th>2011-2018</th> <th>2019</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td></td> <td>8,732,800</td> </tr> <tr> <td>Annual Amounts (US\$)</td> <td>309,551,926</td> <td>30,124,000</td> </tr> </tbody> </table>	Type of supplies to be purchased with Gavi funds	2011-2018	2019	Number of vaccine doses		8,732,800	Annual Amounts (US\$)	309,551,926	30,124,000	
Type of supplies to be purchased with Gavi funds	2011-2018	2019									
Number of vaccine doses		8,732,800									
Annual Amounts (US\$)	309,551,926	30,124,000									
12. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.										
13. Self-procurement:	Not applicable										

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the amount that Gavi has approved.

**14. Co-financing obligations:**

According to the co-financing policy, the Country falls within the group: Initial self-financing

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2019	2020
Number of vaccine doses	607,600	802,000
Value of vaccine doses (US\$)	1,852,841	2,200,610
Total co-financing payments (US\$) (including freight)	1,868,500	2,221,000

**15. Operational support for catch-up campaigns:**

Not applicable

**16. Additional Reporting Requirements:**

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> <li>Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	31 March 2020 15 May 2020
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

**17. Financial clarifications:**

Not applicable

**18. Other conditions:**

Not applicable

Signed by,

On behalf of Gavi



Pascal Bijleveld,  
Managing Director, Country Programmes a.i.  
24 July 2019